<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952561</url>
  </required_header>
  <id_info>
    <org_study_id>IPM 034</org_study_id>
    <nct_id>NCT01952561</nct_id>
  </id_info>
  <brief_title>Expanded Use PK of Dapivirine Vaginal Ring</brief_title>
  <official_title>An Open-label, Parallel-group Pharmacokinetic Trial in Healthy HIV-negative Women to Characterize the Release Profile of Dapivirine Delivered by a Silicone Matrix Ring (Ring 004), Containing 25 mg of Dapivirine, Over Various Ring Use Periods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study will evaluate the vaginal and blood pharmacokinetics of dapivirine from a vaginal ring
      containing 25 mg worn for 1, 2, 4, 8 or 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dapivirine pharmacokinetics in plasma</measure>
    <time_frame>1,2,4,8 or 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1 week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapivirine ring</intervention_name>
    <arm_group_label>2 weeks</arm_group_label>
    <arm_group_label>1 week</arm_group_label>
    <arm_group_label>4 weeks</arm_group_label>
    <arm_group_label>8 weeks</arm_group_label>
    <arm_group_label>12 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Women 18 and â‰¤ 40 years of age who can give written informed consent

          2. Available for all visits and consent to follow all procedures scheduled for the trial

          3. Healthy, based on medical history, vital signs, physical examination, urinalysis,
             laboratory evaluations for genital infections, and laboratory evaluations for
             haematology and chemistry

          4. HIV-negative as determined by an HIV test at the time of enrolment

          5. On a stable form of contraception, defined as:

               -  A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR

               -  Transdermal contraceptive patch for at least 3 months prior to enrolment, OR

               -  Long-acting progestins for at least 6 months prior to enrolment, OR

               -  An IUD inserted at least 3 months prior to enrolment, OR

               -  Have undergone surgical sterilisation at least 3 months prior to enrolment AND
                  willing to use oral contraceptives if necessary to delay menstruation during the
                  vaginal sampling period

          6. Upon pelvic examination at the time of enrolment, the cervix and vagina appear normal
             as determined by the Investigator/Physician

          7. Asymptomatic for genital infections at the time of enrolment

          8. Willing to refrain from the use of topical vaginal medications, vaginal products or
             objects

          9. Documentation of no abnormality on cervical cytology, including grossly bloody smear,
             within 90 days prior to screening

         10. Willing to refrain from participation in any other research trial for the duration of
             this trial

         11. Willing to provide adequate locator information for trial retention purposes and be
             reachable per local standard procedures, e.g. by home visit or telephone, or via
             family or close neighbour contacts

         12. Willing to agree to abstain from all the following for a total of 2 days (48 hours)
             prior to each trial visit:

               -  Penile-vaginal intercourse

               -  Oral contact with her genitalia

         13. Hepatitis B and C negative at the time of enrolment.

        Key Exclusion Criteria:

          1. Currently pregnant or had their last pregnancy outcome within 3 months prior to
             screening

          2. Currently breast-feeding

          3. Currently or within two months of participation in any other clinical research trial
             involving investigational or marketed products prior to screening

          4. Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually
             transmitted infections, or other gynaecological conditions such as vaginal itching,
             pain, or discharge, within 2 weeks prior to enrolment

          5. Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for
             Grading the Severity of Adult and Pediatric Adverse Events;

          6. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding,
             urethral obstruction, incontinence or urge incontinence

          7. Current vulvar or vaginal symptoms/abnormalities that could influence the trial
             results

          8. Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other
             than for infection), or further evaluation

          9. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital
             herpetic infection

         10. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at
             baseline (screening) according to the DAIDS Table for Grading the Severity of Adult
             and Pediatric Adverse Events;

         11. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or
             gynaecologic surgery within 90 days prior to enrolment

         12. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of
             sensitivity/allergy to latex or silicone

         13. Any serious acute, chronic or progressive or signs of cardiac disease, renal failure,
             or severe malnutrition

         14. Have undergone a hysterectomy

         15. Any condition(s) that, in the opinion of the Investigator, might interfere with
             adherence to trial requirements or evaluation of the trial objectives.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>vaginal ring</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

